Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug;63(8):717-24.
doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8.

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

H-J Aubin  1 , A Bobak, J R Britton, C Oncken, C B Billing Jr, J Gong, K E Williams, K R Reeves
Affiliations
Randomized Controlled Trial

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial

H-J Aubin et al. Thorax. 2008 Aug.

Abstract

Background: Varenicline, a new treatment for smoking cessation, has demonstrated significantly greater efficacy over placebo and sustained release bupropion (bupropion SR). A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal nicotine replacement therapy (NRT) for smoking cessation.

Methods: In this 52-week, open-label, randomised, multicentre, phase 3 trial conducted in Belgium, France, The Netherlands, UK and USA, participants were randomly assigned (1:1) to receive varenicline uptitrated to 1 mg twice daily for 12 weeks or transdermal NRT (21 mg/day reducing to 7 mg/day) for 10 weeks. Non-treatment follow-up continued to week 52. The primary outcome was the biochemically confirmed (exhaled carbon monoxide < or = 10 ppm) self-reported continuous abstinence rate (CAR) for the last 4 weeks of the treatment period in participants who had taken at least one dose of treatment. Secondary outcomes included CAR from the last 4 weeks of treatment through weeks 24 and 52, and measures of craving, withdrawal and smoking satisfaction.

Results: A total of 376 and 370 participants assigned to varenicline and NRT, respectively, were eligible for analysis. The CAR for the last 4 weeks of treatment was significantly greater for varenicline (55.9%) than NRT (43.2%; OR 1.70, 95% CI 1.26 to 2.28, p<0.001). The week 52 CAR (NRT, weeks 8-52; varenicline, weeks 9-52) was 26.1% for varenicline and 20.3% for NRT (OR 1.40, 95% CI 0.99 to 1.99, p = 0.056). Varenicline significantly reduced craving (p<0.001), withdrawal symptoms (p<0.001) and smoking satisfaction (p<0.001) compared with NRT. The most frequent adverse event was nausea (varenicline, 37.2%; NRT, 9.7%).

Conclusions: The outcomes of this trial established that abstinence from smoking was greater and craving, withdrawal symptoms and smoking satisfaction were less at the end of treatment with varenicline than with transdermal NRT.

Trial registration number: NCT00143325.

PubMed Disclaimer

Conflict of interest statement

Competing interests: H-JA has received sponsorship to attend scientific meetings, speaker honorariums and consultancy fees from GlaxoSmithKline, Pierre-Fabre Sante, Sanofi-Aventis, Merck-Lipha and Pfizer Inc. AB has received sponsorship to attend scientific meetings, speaker honorariums and consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer Inc. In the past 5 years JRB has received consultancy fees from Xenova and Novartis and his employing institution has received consultancy fees and honoraria on his behalf from Pfizer Inc. CO has received honoraria and consulting fees from Pfizer, nicotine and placebo products for research studies at no cost from GlaxoSmithKline and honoraria from Pri-Med and CME outfitters. CBB, JG, KEW and KRR are employees of Pfizer Inc.

Figures

Figure 1
Figure 1. Study design. W, week; TQD, target quit date; Rand, randomisation; NRT, nicotine replacement therapy; BID, twice daily.
Figure 2
Figure 2. Participant disposition. NRT, nicotine replacement therapy.
Figure 3
Figure 3. Four-week end of treatment CAR (weeks 9–12 for varenicline and weeks 8–11 for NRT) for the Primary Analysis Population (all randomised and treated participants who took at least one dose of study medication). Results of the All Randomised Population CAR for the same period: varenicline, 55.6%; NRT, 42.2% (OR 1.76, 95% CI 1.31 to 2.36; p<0.001). CAR, continuous abstinence rate; NRT, nicotine replacement therapy; OR, odds ratio; CI, confidence intervals.
Figure 4
Figure 4. CAR through week 52 (weeks 9–52 for varenicline and weeks 8–52 for NRT) for the Primary Analysis Population (all randomised and treated participants who took at least one dose of study medication). Results of the All Randomised Population CAR for the same period: varenicline, 25.9%; NRT, 19.8% (OR 1.44, 95% CI 1.02 to 2.03; p = 0.040). CAR, continuous abstinence rate; NRT, nicotine replacement therapy; OR, odds ratio; CI, confidence intervals.
See this image and copyright information in PMC

Comment in

References

    1. Fiore M. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guidelines. Respir Care 2000;45:1196–9 - PubMed
    1. Centers for Disease Control and Prevention Cigarette smoking among adults – United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:642–5 - PubMed
    1. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29–38 - PubMed
    1. Tønnesen P, Carrozzi L, Fagerström K, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007;29:390–417 - PubMed
    1. US Food and Drug Administration Electric orange book: approved drug products with therapeutic equivalence evaluations. 2007. http://www.fda.gov/cder/ob/default.htm (accessed 24 January 2008)

Publication types

Associated data